Enrichment of SHIP2 by immunoprecipitation from cultured cells and measurement of the phosphatase activity in the precipitate revealed that 1 mM metformin reduces SHIP2 activity by 24% in myotubes and 14% in podocytes (Fig. 1C, D) but not in hepatoma cells (Supplemental Fig. S2A). Here, INPPL1 is linked to hepatocellular carcinoma.